Safety and immunogenicity of an FP9-vectored candidate tuberculosis vaccine (FP85A), alone and with candidate vaccine MVA85A in BCG-vaccinated healthy adults: A phase i clinical trial

Human Vaccines and Immunotherapeutics

Volumn 9, Issue 1, 2013, Pages 50-62

  Rowland, Rosalind ^a   Pathan, Ansar A ^a,c   Satti, Iman ^a   Poulton, Ian D ^a   Matsumiya, Magali M L ^a   Whittaker, Megan ^a   Minassian, Angela M ^a   O'Hara, Geraldine A ^a   Hamill, Matthew ^a,d   Scott, Janet T ^a,e   Harris, Stephanie A ^a   Poyntz, Hazel C ^a   Bateman, Cynthia ^a   Meyer, Joel ^a   Williams, Nicola ^b   Gilbert, Sarah C ^a   Lawrie, Alison M ^a   Hill, Adrian V S ^a   McShane, Helen ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c BRUNEL UNIVERSITY   (United Kingdom)

^d MRC HUMAN NUTRITION RESEARCH   (United Kingdom)

^e UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

Heterologous prime boost regimes; Phase I clinical trial; Poxvirus vectored subunit vaccines; Tuberculosis vaccines

Indexed keywords

BACTERIAL VACCINE; BCG VACCINE; FP 85A; IMMUNOGLOBULIN G ANTIBODY; RECOMBINANT VACCINE; UNCLASSIFIED DRUG;

ADULT; ANTIBODY PRODUCTION; ANTIGEN SPECIFICITY; ARTHRALGIA; ARTICLE; BCG VACCINATION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; COMBINATION CHEMOTHERAPY; COMMON COLD; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOKINE RESPONSE; DISEASE SEVERITY; DIZZINESS; DRUG ANTAGONISM; DRUG CROSS REACTIVITY; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; EX VIVO STUDY; FATIGUE; GASTROINTESTINAL REFLUX; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; IMMUNOGENICITY; INJECTION SITE ERYTHEMA; INJECTION SITE INDURATION; INJECTION SITE PAIN; INJECTION SITE PRURITUS; INJECTION SITE WARMTH; LYMPHADENOPATHY; MALAISE; MONOTHERAPY; MYALGIA; NAUSEA; NORMAL HUMAN; PHASE 1 CLINICAL TRIAL; RIGOR; SCAR FORMATION; SHOULDER PAIN; SLEEP DISORDER; SYSTEMIC DISEASE;

HETEROLOGOUS PRIME-BOOST REGIMES; PHASE I CLINICAL TRIAL; POXVIRUS-VECTORED SUBUNIT VACCINES; TUBERCULOSIS VACCINES;

ADULT; ANTIBODIES, BACTERIAL; DRUG TOXICITY; ENZYME-LINKED IMMUNOSORBENT ASSAY; ENZYME-LINKED IMMUNOSPOT ASSAY; FEMALE; FLOW CYTOMETRY; HUMANS; IMMUNOGLOBULIN G; MALE; MIDDLE AGED; T-LYMPHOCYTES; TUBERCULOSIS VACCINES; VACCINATION; VIRAL VACCINES; YOUNG ADULT;

EID: 84874748140     PISSN: 21645515     EISSN: 2164554X     Source Type: Journal    
DOI: 10.4161/hv.22464     Document Type: Article

References (37)

1. Global Tuberculosis Control. WHO report 2011. Geneva: World Health Organisation, 2011.
2. Trunz BB, Fine P, Dye C. Effect of BCG vaccination on childhood tuberculous meningitis and miliary tuberculosis worldwide: a meta-analysis and assessment of cost-effectiveness. Lancet 2006; 367:1173-80; PMID:16616560; http://dx.doi.org/10.1016/S0140-6736(06)68507-3.
3. Colditz GA, Brewer TF, Berkey CS, Wilson ME, Burdick E, Fineberg HV, et al. Efficacy of BCG vaccine in the prevention of tuberculosis. Meta-analysis of the published literature. JAMA 1994; 271:698-702; PMID:8309034; http://dx.doi.org/10.1001/jama.1994.03510330076038.
4. Revised BCG vaccination guidelines for infants at risk for HIV infection. Wkly Epidemiol Rec 2007; 82:193-6; PMID:17526121.
5. Flynn JL. Immunology of tuberculosis and implications in vaccine development. Tuberculosis (Edinb) 2004; 84:93-101; PMID:14670350; http://dx.doi.org/10.1016/j.tube.2003.08.010.
6. Vuola JM, Keating S, Webster DP, Berthoud T, Dunachie S, Gilbert SC, et al. Differential immunogenicity of various heterologous prime-boost vaccine regimens using DNA and viral vectors in healthy volunteers. J Immunol 2005; 174:449-55; PMID:15611270.
7. Scriba TJ, Tameris M, Smit E, van der Merwe L, Hughes EJ, Kadira B, et al. A phase IIa trial of the new tuberculosis vaccine, MVA85A, in HIVand/or Mycobacterium tuberculosis-infected adults. Am J Respir Crit Care Med 2012; 185:769-78; PMID:22281831; http://dx.doi.org/10.1164/rccm.201108-1548OC.
8. Minassian AM, Rowland R, Beveridge NE, Poulton ID, Satti I, Harris S, et al. A Phase I study evaluating the safety and immunogenicity of MVA85A, a candidate TB vaccine, in HIV-infected adults. BMJ Open 2011; 1:e000223; PMID:22102640; http://dx.doi.org/10.1136/bmjopen-2011-000223.
9. Ota MO, Odutola AA, Owiafe PK, Donkor S, Owolabi OA, Brittain NJ, et al. Immunogenicity of the tuberculosis vaccine MVA85A is reduced by coadministration with EPI vaccines in a randomized controlled trial in Gambian infants. Sci Transl Med 2011; 3:88ra56; PMID:21697532; http://dx.doi.org/10.1126/ scitranslmed. 3002461.
10. Scriba TJ, Tameris M, Mansoor N, Smit E, van der Merwe L, Mauff K, et al. Dose-finding study of the novel tuberculosis vaccine, MVA85A, in healthy BCGvaccinated infants. J Infect Dis 2011; 203:1832-43; PMID:21606542; http://dx.doi.org/10.1093/infdis/jir195.
11. Sander CR, Pathan AA, Beveridge NE, Poulton I, Minassian A, Alder N, et al. Safety and immunogenicity of a new tuberculosis vaccine, MVA85A, in Mycobacterium tuberculosis-infected individuals. Am J Respir Crit Care Med 2009; 179:724-33; PMID:19151191; http://dx.doi.org/10.1164/rccm.200809-1486OC.
12. Brookes RH, Hill PC, Owiafe PK, Ibanga HB, Jeffries DJ, Donkor SA, et al. Safety and immunogenicity of the candidate tuberculosis vaccine MVA85A in West Africa. PLoS One 2008; 3:e2921; PMID:18698342; http://dx.doi.org/10.1371/ journal.pone.0002921.
13. Hawkridge T, Scriba TJ, Gelderbloem S, Smit E, Tameris M, Moyo S, et al. Safety and immunogenicity of a new tuberculosis vaccine, MVA85A, in healthy adults in South Africa. J Infect Dis 2008; 198:544-52; PMID:18582195; http://dx.doi.org/10.1086/590185.
14. Beveridge NE, Price DA, Casazza JP, Pathan AA, Sander CR, Asher TE, et al. Immunisation with BCG and recombinant MVA85A induces long-lasting, polyfunctional Mycobacterium tuberculosis-specific CD4+ memory T lymphocyte populations. Eur J Immunol 2007; 37:3089-100; PMID:17948267; http://dx.doi.org/10.1002/eji.200737504.
15. Pathan AA, Sander CR, Fletcher HA, Poulton I, Alder NC, Beveridge NE, et al. Boosting BCG with recombinant modified vaccinia ankara expressing antigen 85A: different boosting intervals and implications for efficacy trials. PLoS One 2007; 2:e1052; PMID:17957238; http://dx.doi.org/10.1371/journal.pone.0001052.
16. McShane H, Pathan AA, Sander CR, Keating SM, Gilbert SC, Huygen K, et al. Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans. Nat Med 2004; 10:1240-4; PMID:15502839; http://dx.doi.org/10.1038/nm1128.
17. Williams A, Goonetilleke NP, McShane H, Clark SO, Hatch G, Gilbert SC, et al. Boosting with poxviruses enhances Mycobacterium bovis BCG efficacy against tuberculosis in guinea pigs. Infect Immun 2005; 73:3814-6; PMID:15908420; http://dx.doi.org/10.1128/IAI.73.6.3814-3816.2005.
18. Walther M, Woodruff J, Edele F, Jeffries D, Tongren JE, King E, et al. Innate immune responses to human malaria: heterogeneous cytokine responses to bloodstage Plasmodium falciparum correlate with parasitological and clinical outcomes. J Immunol 2006; 177:5736-45; PMID:17015763.
19. Webster DP, Dunachie S, McConkey S, Poulton I, Moore AC, Walther M, et al. Safety of recombinant fowlpox strain FP9 and modified vaccinia virus Ankara vaccines against liver-stage P. falciparum malaria in non-immune volunteers. Vaccine 2006; 24:3026-34; PMID:16488059; http://dx.doi.org/10.1016/j.vaccine. 2005.10.058.
20. Rowland R, Brittain N, Poulton ID, Minassian AM, Sander C, Porter DW, et al. A review of the tolerability of the candidate TB vaccine, MVA85A compared with BCG and Yellow Fever vaccines, and correlation between MVA85A vaccine reactogenicity and cellular immunogenicity. Trials in Vaccinology 2012; 1:27-35; http://dx.doi.org/10.1016/j.trivac.2012.07.001.
21. Keefer MC, Frey SE, Elizaga M, Metch B, De Rosa SC, Barroso PF, et al.; NIAID HIV Vaccine Trials Network. A phase I trial of preventive HIV vaccination with heterologous poxviral-vectors containing matching HIV-1 inserts in healthy HIV-uninfected subjects. Vaccine 2011; 29:1948-58; PMID:21216311; http://dx.doi.org/10.1016/j.vaccine.2010.12.104.
22. Porter DW, Thompson FM, Berthoud TK, Hutchings CL, Andrews L, Biswas S, et al. A human Phase I/IIa malaria challenge trial of a polyprotein malaria vaccine. Vaccine 2011; 29:7514-22; PMID:21501642; http://dx.doi.org/10.1016/j. vaccine.2011.03.083.
23. Currier JR, Ngauy V, de Souza MS, Ratto-Kim S, Cox JH, Polonis VR, et al. Phase I safety and immunogenicity evaluation of MVA-CMDR, a multigenic, recombinant modified vaccinia Ankara-HIV-1 vaccine candidate. PLoS One 2010; 5:e13983; PMID:21085591; http://dx.doi.org/10.1371/journal.pone.0013983.
24. Guerra S, Lopez-Fernandez LA, Conde R, Pascual-Montano A, Harshman K, Esteban M. Microarray analysis reveals characteristic changes of host cell gene expression in response to attenuated modified vaccinia virus Ankara infection of human HeLa cells. J Virol 2004; 78:5820-34; PMID:15140980; http://dx.doi.org/ 10.1128/JVI.78.11.5820-5834.2004.
25. Sawant KV, Cho H, Lyons M, Ly LH, McMurray DN. Guinea pig neutrophil-macrophage interactions during infection with Mycobacterium tuberculosis. Microbes Infect 2010; 12:828-37; PMID:20685396; http://dx.doi.org/10.1016/j.micinf.2010.05.009.
26. Sterling TR, Dorman SE, Chaisson RE, Ding L, Hackman J, Moore K, et al. Human immunodeficiency virus-seronegative adults with extrapulmonary tuberculosis have abnormal innate immune responses. Clin Infect Dis 2001; 33:976-82; PMID:11528568; http://dx.doi.org/10.1086/322670.
27. Tuberculosis. Green Book: Department of Health, 2011:403-7.
28. Laidlaw SM, Skinner MA. Comparison of the genome sequence of FP9, an attenuated, tissue culture-adapted European strain of Fowlpox virus, with those of virulent American and European viruses. J Gen Virol 2004; 85:305-22; PMID:14769888; http://dx.doi.org/10.1099/vir.0.19568-0.
29. Qingzhong Y, Barrett T, Brown TD, Cook JK, Green P, Skinner MA, et al. Protection against turkey rhinotracheitis pneumovirus (TRTV) induced by a fowlpox virus recombinant expressing the TRTV fusion glycoprotein (F). Vaccine 1994; 12:569-73; PMID:8036832; http://dx.doi.org/10.1016/0264-410X(94)90319-0.
30. McShane H, Behboudi S, Goonetilleke N, Brookes R, Hill AV. Protective immunity against Mycobacterium tuberculosis induced by dendritic cells pulsed with both CD8(+)-and CD4(+)-T-cell epitopes from antigen 85A. Infect Immun 2002; 70:1623-6; PMID:11854254; http://dx.doi.org/10.1128/IAI.70.3.1623-1626.2002.
31. Howles S, Guimaraes-Walker A, Yang H, Hancock G, di Gleria K, Tarragona-Fiol T, et al. Vaccination with a modified vaccinia virus Ankara (MVA)-vectored HIV-1 immunogen induces modest vector-specific T cell responses in human subjects. Vaccine 2010; 28:7306-12; PMID:20816902; http://dx.doi.org/ 10.1016/j.vaccine.2010.08.077.
32. Meyer VS, Kastenmuller W, Gasteiger G, Franz-Wachtel M, Lamkemeyer T, Rammensee HG, et al. Long-term immunity against actual poxviral HLA ligands as identified by differential stable isotope labeling. J Immunol 2008; 181:6371-83; PMID:18941228.
33. Strug I, Calvo-Calle JM, Green KM, Cruz J, Ennis FA, Evans JE, et al. Vaccinia peptides eluted from HLADR1 isolated from virus-infected cells are recognized by CD4+ T cells from a vaccinated donor. J Proteome Res 2008; 7:2703-11; PMID:18507432; http://dx.doi.org/10.1021/pr700780x.
34. Calvo-Calle JM, Strug I, Nastke MD, Baker SP, Stern LJ. Human CD4+ T cell epitopes from vaccinia virus induced by vaccination or infection. PLoS Pathog 2007; 3:1511-29; PMID:17937498; http://dx.doi.org/10.1371/journal.ppat.0030144.
35. Terajima M, Cruz J, Leporati AM, Demkowicz WE Jr., Kennedy JS, Ennis FA. Identification of vaccinia CD8+ T-cell epitopes conserved among vaccinia and variola viruses restricted by common MHC class I molecules, HLA-A2 or HLA-B7. Hum Immunol 2006; 67:512-20; PMID:16829305; http://dx.doi.org/10.1016/j.humimm. 2005.12.004.
36. Oseroff C, Kos F, Bui HH, Peters B, Pasquetto V, Glenn J, et al. HLA class I-restricted responses to vaccinia recognize a broad array of proteins mainly involved in virulence and viral gene regulation. Proc Natl Acad Sci U S A 2005; 102:13980-5; PMID:16172378; http://dx.doi.org/10.1073/pnas.0506768102.
37. Drexler I, Staib C, Kastenmuller W, Stevanovic S, Schmidt B, Lemonnier FA, et al. Identification of vaccinia virus epitope-specific HLA-A*0201-restricted T cells and comparative analysis of smallpox vaccines. Proc Natl Acad Sci U S A 2003; 100:217-22; PMID:12518065; http://dx.doi.org/10.1073/pnas.262668999.